JPH05509309A - 2―フェニル―1,2―ベンズイソセレナゾール―3(2h)―オンの利用法 - Google Patents
2―フェニル―1,2―ベンズイソセレナゾール―3(2h)―オンの利用法Info
- Publication number
- JPH05509309A JPH05509309A JP3512768A JP51276891A JPH05509309A JP H05509309 A JPH05509309 A JP H05509309A JP 3512768 A JP3512768 A JP 3512768A JP 51276891 A JP51276891 A JP 51276891A JP H05509309 A JPH05509309 A JP H05509309A
- Authority
- JP
- Japan
- Prior art keywords
- cisplatin
- ebselen
- pharmaceutical
- administration
- side effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (10)
- 1.シスプラチンの医薬投与により誘起される副作用を治療及び予防する医薬品 の製造のための2−フェニル−1,2−ベンズイソセレナゾール−3(2H)− オンの使用。
- 2.新生物症の治療及びシスプラチンの医薬投与により誘起される副作用を予防 する10mg〜100mgのシスプラチンと10mg〜2000mgのEbse lenを含む医薬品の製造のためのシスプラチンとEbselenの組合せの使 用。
- 3.シスプラチン及びEbselenがかかる2種の薬剤を近隣に分離した形態 で含む、医療キット集合体又は容器の形態である請求項2記載の使用。
- 4.Ebselen及び常用の医薬補助剤を含むシスプラチンの副作用を治療す るための医薬組成物。
- 5.Ebselenをシスプラチンと組合せて、これら2種の薬剤を近隣に分離 した形態で含む、医療キット、集合体又は容器の形態で含む、シスプラチンの副 作用を治療するための医薬組成物。
- 6.シスプラチンの投与前、同時または後にEbselenを投与することでシ スプラチンの副作用を治療する方法。
- 7.Ebselenを投与するに当って、経口的または非経口的に1日に10m g〜2000mgを1回または数回に分け投与する請求項6に記載の方法。
- 8.シスプラチン及びEbselenの組合せの投与により新生物症を治療する に当って、医薬が10mg〜100mgのシスプラチン及び10mg〜2000 mgのEbselenを含む治療方法。
- 9.10mg〜100mgのシスプラチン及び10mg〜2000mgのEbs elen並びに常用の医薬補助剤を含んでなる、新生物症治療用医薬組成物。
- 10.Ebselenを10mg〜2000mg含む請求項9記載の医薬組成物 。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4024885A DE4024885C2 (de) | 1990-08-06 | 1990-08-06 | Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on |
DE4024885.2 | 1990-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05509309A true JPH05509309A (ja) | 1993-12-22 |
JP3084062B2 JP3084062B2 (ja) | 2000-09-04 |
Family
ID=6411708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03512768A Expired - Lifetime JP3084062B2 (ja) | 1990-08-06 | 1991-07-31 | 2―フェニル―1,2―ベンズイソセレナゾール―3(2h)―オンの利用法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0542807B1 (ja) |
JP (1) | JP3084062B2 (ja) |
AT (1) | ATE171621T1 (ja) |
CA (1) | CA2088760C (ja) |
DE (2) | DE4024885C2 (ja) |
DK (1) | DK0542807T3 (ja) |
ES (1) | ES2123510T3 (ja) |
WO (1) | WO1992002221A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005510537A (ja) * | 2001-11-29 | 2005-04-21 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 化学療法の所望されない効果を改善する方法および組成物 |
JP2005519991A (ja) * | 2001-06-08 | 2005-07-07 | 北京大学 | 抗炎症、抗ウイルスおよび抗血栓症活性を有するベンゾイソセレンアゾール誘導体ならびにそれらの使用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2553434B2 (ja) * | 1992-04-28 | 1996-11-13 | 第一製薬株式会社 | 粒状製剤 |
ATE190487T1 (de) | 1993-10-27 | 2000-04-15 | Daiichi Seiyaku Co | Granuläre zubereitung |
DK0826370T3 (da) * | 1996-08-27 | 2002-10-07 | Nattermann A & Cie | Lægemiddel indeholdende 2-phenyl-1, 2-benzisoselenazol-3(2H)-on til behandling af Alzheimers sygdom |
DE19825746A1 (de) * | 1998-06-09 | 1999-12-16 | Biosyn Arzneimittel Gmbh | Kombination von Selen-haltigen Verbindungen mit Zytostatika |
MXPA04002707A (es) * | 2001-09-24 | 2005-06-06 | Tosk Inc | Formulaciones de cisplatina con toxicidad reducida y metodos para utilizar las mismas. |
WO2003057207A1 (en) | 2002-01-04 | 2003-07-17 | Sound Pharmaceuticals Incorporated | Methods for treating hearing loss |
AU2006220626A1 (en) * | 2005-03-08 | 2006-09-14 | Sound Pharmaceuticals Incorporated | Methods and compositions for treating cancer |
GB201102248D0 (en) | 2011-02-09 | 2011-03-23 | Isis Innovation | Treatment of bipolar disorder |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3027073C2 (de) * | 1980-07-17 | 1985-03-07 | A. Nattermann & Cie GmbH, 5000 Köln | Pharmazeutische Präparate, enthaltend 2-Phenyl-1,2-benzisoselenazol-3(2H)-on |
DE3616923A1 (de) * | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
DE3638124C2 (de) * | 1986-11-08 | 1996-09-05 | Nattermann A & Cie | Neue pharmazeutische Verwendung von Ebselen |
DE3821392A1 (de) * | 1988-06-24 | 1989-12-28 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen) |
-
1990
- 1990-08-06 DE DE4024885A patent/DE4024885C2/de not_active Expired - Lifetime
-
1991
- 1991-07-31 ES ES91914052T patent/ES2123510T3/es not_active Expired - Lifetime
- 1991-07-31 DE DE69130292T patent/DE69130292T2/de not_active Expired - Lifetime
- 1991-07-31 AT AT91914052T patent/ATE171621T1/de not_active IP Right Cessation
- 1991-07-31 WO PCT/EP1991/001438 patent/WO1992002221A1/en active IP Right Grant
- 1991-07-31 CA CA002088760A patent/CA2088760C/en not_active Expired - Lifetime
- 1991-07-31 JP JP03512768A patent/JP3084062B2/ja not_active Expired - Lifetime
- 1991-07-31 DK DK91914052T patent/DK0542807T3/da active
- 1991-07-31 EP EP91914052A patent/EP0542807B1/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005519991A (ja) * | 2001-06-08 | 2005-07-07 | 北京大学 | 抗炎症、抗ウイルスおよび抗血栓症活性を有するベンゾイソセレンアゾール誘導体ならびにそれらの使用 |
JP2005510537A (ja) * | 2001-11-29 | 2005-04-21 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 化学療法の所望されない効果を改善する方法および組成物 |
Also Published As
Publication number | Publication date |
---|---|
DK0542807T3 (da) | 1999-06-21 |
ES2123510T3 (es) | 1999-01-16 |
CA2088760C (en) | 2002-05-07 |
DE4024885A1 (de) | 1992-02-13 |
DE4024885C2 (de) | 2002-07-18 |
ATE171621T1 (de) | 1998-10-15 |
CA2088760A1 (en) | 1993-02-01 |
EP0542807B1 (en) | 1998-09-30 |
DE69130292D1 (de) | 1998-11-05 |
JP3084062B2 (ja) | 2000-09-04 |
DE69130292T2 (de) | 1999-04-08 |
EP0542807A1 (en) | 1993-05-26 |
WO1992002221A1 (en) | 1992-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100272835B1 (ko) | 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물 | |
US20060089313A1 (en) | Methods and compositions for ameliorating the undesirable effects of chemotherapy | |
DE69921175T2 (de) | Hexapeptide mit stabilisierter disulfidbindung und seine derivate zur regulation des metabolismus, der proliferation, differenzierung und apoptose | |
AU619022B2 (en) | Pharmaceutical compositions for the inhibition of tumor metastasis | |
JPH05509309A (ja) | 2―フェニル―1,2―ベンズイソセレナゾール―3(2h)―オンの利用法 | |
US5049396A (en) | Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment | |
KR20170125991A (ko) | 실리빈 및 ve 함유 약학 조성물 | |
Turdiyev et al. | CHOLERETIC ACTIVITY OF RUTANA AT THERAPEUTIC APPLICATION IN RATS WITH HELIOTRIN HEPATITIS | |
JP2014517065A (ja) | ホスファチジルコリンを有効成分として含む抗癌剤の毒性減少用組成物(Compositioncomprisingphosphstidylcholineasanactiveingredientforattenuatingtoxicityofanticanceragent) | |
Ajibade et al. | Some morphological and biochemical changes in the kidney of adult Wistar rats following aluminium chloride exposures | |
EP0313654B1 (en) | Drug for prophylaxis and treatment of hepatopathy | |
KR950008767B1 (ko) | 에브셀렌(Ebselen)의 새로운 의약적 용도 | |
US5385726A (en) | Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one | |
JP2024016228A (ja) | アセトアミノフェン(apap)によって引き起こされる毒性を予防、低減または根絶するための方法および組成物 | |
US20230090982A1 (en) | Drug for treating coronaviral and retroviral infections and hepatitis c | |
SA94140746B1 (ar) | مركب علاجي من /tamoxifen cisplatin للسرطانات في الانسان | |
JP2000510114A (ja) | 抗酸化剤化合物 | |
KR20030001659A (ko) | 흰점박이꽃무지 추출물 및 이의 용도 | |
RU2250768C2 (ru) | Фармацевтическая композиция и способ лечения прогрессирующего фиброза и цирроза печени | |
EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
JPH08509961A (ja) | 低密度リポタンパク質および細胞毒性物質の使用 | |
RU2197984C1 (ru) | Способ лечения различных форм туберкулеза легких, в том числе резистентных к противотуберкулезной химиотерапии | |
FR2838965A1 (fr) | Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme | |
JP6801908B1 (ja) | ベネトクラクスの水溶性高分子誘導体 | |
RU2283112C1 (ru) | Противовоспалительное лекарственное средство |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080630 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090630 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100630 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110630 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110630 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120630 Year of fee payment: 12 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120630 Year of fee payment: 12 |